OncoVista Innovative Therapies is a San Antonio, Texas-based
drug development company employing a blend of innovative drug discovery,
registration strategies and emerging technologies in order to bring to market
less toxic and highly effective anti-cancer drugs.
As part of this model, the company focuses on acquisition
candidates previously tested in human clinical trials or animal models, as well
as technologies with potential to improve the delivery or targeting of
previously tested, and in some cases marketed, anti-cancer agents.
From here, OncoVista intends to develop the candidates into
novel, highly efficacious therapies to be marketed and commercialized via
corporate partnerships with industry leaders, generating revenues through
licensing/milestone fees and royalties flowing from out-licensing/partner
agreements.
OncoVista’s current focus is on advancing its oncology drug
candidate pipeline, which includes Cordycepin (OVI-123), in phase I/II clinical
trials for the treatment of Refractory TdT Positive Leukemias; and L-Nucleoside
Conjugates (OVI-117), under clinical development for the treatment of colon
cancer.
After dealing with capital snags in 2008, which resulted in
halting clinical trials of Cordycepin in 2009, recent corporate announcements signal
that OncoVista is getting back on course. The company earlier this month
announced two sources of bridge financing (Chicago Venture Partners of Chicago
and a high net worth individual), expected to accelerate the process of getting
the company operational again. With step one of the financing process underway,
OncoVista is now working on a larger equity deal (step two) for the funding of
both trials.
Initiatives are headed by CEO Dr. Alexander L. Weis, who has
more than 20 years in the biopharmaceutical industry and more than 60
publications and 28 patents. Dr. Weis is supported by an experienced board of
directors, as well as a clinical advisory board comprised of members with key
roles in the development of a variety of oncology/chemotherapy drugs, including
Taxol®, Hycamtin®, Eloxatin™, Taxotere®, Camptosar®, Taxotere®, Campath® and
Tarceva®.
With a bit of wind back in its sails, OncoVista is actively
pursuing the advancement of its oncology drug candidate pipeline for the
treatment of leukemia and colon cancer.
For more information visit www.oncovista.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment